Sentinext Therapeutics Sdn Bhd (791683-X)

Online Profile

Sentinext Therapeutics, a Malaysian biotechnology company, was formed in 2009 to develop safe and efficacious vaccines and therapeutics for tropical infectious diseases. Within the next ten years, Sentinext aims to become an important vaccine and immunotherapy company based in the Asia-Pacific region, renowned for its expertise in infectious diseases endemic to that part of the world.

Sentinext is built on research spanning over 20 years by eminent Malaysian scientist Dr. Jane Cardosa, who is internationally renowned for her work on tropical diseases and viruses such as EV71, dengue and viral encephalitis. Sentinext was formed by Dr. Jane Cardosa and Peter Wulff, the latter a seasoned biotechnology entrepreneur who co-founded two European healthcare start-ups, NeuroSearch A/S and Bavarian Nordic A/S. Both companies were successfully listed on European stock exchanges. Mr. Wulff was also CEO of Bavarian Nordic for 13 years.

Sentinext is currently designing and constructing virus-like particles for its vaccines under development. These virus ‘look-alike’ particles will trigger production of the necessary antibodies to fight off the virus infection. It is scientifically much more complex, but will result in a more efficacious and safer vaccine.